Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients

NCT01305460 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT01305460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01305460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 1/2
Overall status
Completed
Start date
July 5, 2011
Completion date
November 16, 2015
Enrollment
27 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome